ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. Its developing products include Pimavanserin for the treatment of Parkinson's disease psychosis in Phase III trials; Pimavanserin as a co-therapy for schizophrenia in Phase II trials; ACP-104 for the treatment of schizophrenia in Phase IIb clinical trials; Pimavanserin for sleep maintenance insomnia in Phase II trials; AGN-XX and AGN-YY for neuropathic pain in Phase II trials; and AC-262271 for glaucoma in Phase I trials. The company's developing pipeline also consists of ACP-105 for endocrine indications in IND-track development stage; ACP-106 for neuropsychiatry and sleep indications in IND-track development stage; Serotonin program for neuropsychiatry and sleep indications in preclinical stage; pro-cognitive antipsychotic (PCAP) program for schizophrenia in preclinical stage; Muscarinic program for neuropsychiatry and other indications in preclinical stage; and Cannabinoid CB1 program for obesity in preclinical stage. The company has collaboration agreements with Allergan, Inc. to discover, develop, and commercialize new therapeutics for ophthalmic indications, selective muscarinic drugs for the treatment of glaucoma, and new therapeutics for neuropathic pain. ACADIA Pharmaceuticals, formerly known as Receptor Technologies, Inc., was founded in 1993. The company is headquartered in San Diego, California.